RE: We need SNG00117 Dec 2021 08:17
Managed Access Program
In September 2020, Synairgen plc signed an agreement with Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, to launch a Managed Access Program for Synairgen’s inhaled interferon beta, SNG001, in the UK and the EU for the treatment of hospitalised COVID-19 patients.
Healthcare professionals in the EU can obtain details about the SNG001 Managed Access Program by calling the customer service team at +44(0)1283 494340 or emailing medicineaccess@clinigengroup.com.
Patients seeking information should contact their physician.